Endocrine therapy has proven benefit for women with hormone-sensitive breast cancers [19], and treatment with 5 or more years of adjuvant endocrine therapy has become standard-of-care following breast conserving surgery for those with hormone receptor (HR) positive breast cancers. Here, NR4A1 is linked to breast carcinoma.